|
ACBD3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 9.85050000457122E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
7.13030000043524E-07 |
| Normal-vs-Stage2 |
1.59686999999797E-05 |
| Normal-vs-Stage3 |
1.29829999995223E-06 |
| Normal-vs-Stage4 |
1.87336999999399E-05 |
| Stage1-vs-Stage2 |
4.320200E-01 |
| Stage1-vs-Stage3 |
7.101400E-01 |
| Stage1-vs-Stage4 |
5.412400E-01 |
| Stage2-vs-Stage3 |
6.362000E-01 |
| Stage2-vs-Stage4 |
8.817000E-01 |
| Stage3-vs-Stage4 |
7.608600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.07489999965094E-07 |
| Normal-vs-AfricanAmerican |
5.655800E-02 |
| Normal-vs-Asian |
1.05999999999717E-06 |
| Caucasian-vs-AfricanAmerican |
1.338580E-01 |
| Caucasian-vs-Asian |
3.529800E-01 |
| AfricanAmerican-vs-Asian |
4.384000E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.67089999947301E-07 |
| Normal-vs-Female |
4.45159999973299E-07 |
| Male-vs-Female |
3.188400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.1179999999954E-05 |
| Normal-vs-Age(41-60Yrs) |
1.06320000026194E-07 |
| Normal-vs-Age(61-80Yrs) |
2.3041000000168E-06 |
| Normal-vs-Age(81-100Yrs) |
2.138400E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.102600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.736200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.980400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.388200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.418400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.327200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.854000E-02 |
| Classical-VS-Follicular |
7.55159999999977E-05 |
| Classical-VS-Other |
7.272300E-02 |
| Classical-VS-Normal |
8.1238000000039E-05 |
| Tall-VS-Follicular |
2.067000E-01 |
| Tall-VS-Other |
1.813810E-01 |
| Tall-VS-Normal |
3.9188999999995E-05 |
| Follicular-VS-Other |
6.286200E-01 |
| Follicular-VS-Normal |
5.16189979649084E-10 |
| Other-VS-Normal |
6.587300E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.07280004061295E-09 |
| Normal-vs-N1 |
1.46769999997964E-06 |
| N0-vs-N1 |
7.603200E-01 |
|
|
